## Acute Urinary Retention (AUR) in BPH: Clinical Context This patient has **acute urinary retention** superimposed on chronic BPH: - **Precipitant**: Likely acute decompensation (infection, constipation, medication, or natural disease progression) despite prior good control on tamsulosin - **High PVR post-catheterization** (380 mL): Indicates significant residual obstruction - **Mild renal impairment** (Cr 1.4 from 1.0): Suggests obstructive uropathy - **Catheter-dependent**: Cannot void spontaneously after initial drainage ## Management of Acute Retention in BPH ```mermaid flowchart TD A[Acute urinary retention]:::outcome --> B[Catheterize bladder]:::action B --> C[Drain urine, assess PVR]:::action C --> D{Identify reversible cause?}:::decision D -->|Yes: UTI, constipation, medication| E[Treat cause + optimize alpha-blocker]:::action D -->|No clear cause| F[Optimize alpha-blocker ± add 5-ARI]:::action E --> G[Leave catheter 3-5 days]:::action F --> G G --> H[Trial of void after optimization]:::decision H -->|Successful: PVR <100 mL| I[Remove catheter, continue medical therapy]:::outcome H -->|Failed: PVR >200 mL| J[TURP or other definitive surgery]:::action ``` ## Why Trial of Void (TOV) After Catheter Rest? **Key Point:** The standard approach to AUR in BPH is: 1. **Catheterize** to relieve obstruction and allow bladder recovery 2. **Optimize medical therapy** (ensure adequate alpha-blocker dosing; consider adding 5-ARI) 3. **Leave catheter 3–5 days** to allow bladder detrusor recovery and reduce edema 4. **Perform TOV** after optimization 5. **Assess outcome**: If PVR <100 mL, remove catheter; if PVR >200 mL, proceed to TURP **High-Yield:** The **success rate of TOV** in first AUR is 40–50% with medical optimization alone. Factors favoring success: - Younger age - First episode of retention - Identifiable reversible cause - Good response to alpha-blockers historically ## Why Not Immediate Catheter Removal? **Warning:** Removing the catheter immediately without a period of bladder rest risks: - **Re-retention** (high recurrence rate without optimization) - **Failure of TOV** due to bladder edema and detrusor decompensation - **Repeated catheterization** and increased infection risk ## Why Not TURP Immediately? **Clinical Pearl:** TURP is **not indicated** as the first step in AUR. It is reserved for: - **Failed TOV** (persistent PVR >200 mL or recurrent retention after successful initial void) - **Patient preference** after counseling - **Severe obstruction** with renal impairment not responding to medical therapy This patient has **not yet been given a fair trial of optimized medical therapy**, so TURP is premature. ## Why Not Higher-Dose Alpha-Blocker or 5-ARI Alone? | Approach | Rationale | |----------|----------| | **Higher-dose tamsulosin** | Tamsulosin 0.4 mg is already the standard dose; 0.8 mg offers minimal additional benefit and increases side effects | | **5-ARI monotherapy without catheter rest** | 5-ARI works slowly (3–6 months); patient cannot wait; must combine with alpha-blocker and allow bladder recovery | | **Immediate catheter removal** | Bladder is decompensated; PVR 380 mL indicates persistent obstruction; TOV will fail without rest and optimization | **High-Yield:** The **combination of alpha-blocker + 5-ARI** is more effective than either alone in AUR, but only **after catheter rest** allows bladder recovery. ## Expected Timeline 1. **Days 0–3**: Catheter in place, bladder drains, edema resolves 2. **Day 3**: Optimize alpha-blocker (ensure 0.4 mg daily); add finasteride 5 mg daily or dutasteride 0.5 mg daily 3. **Day 3–5**: Perform TOV (clamp catheter, assess spontaneous voiding) 4. **Post-TOV**: If PVR <100 mL, remove catheter; if >200 mL, plan TURP [cite:Campbell-Walsh Urology 12e Ch 99; Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.